BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 12639642)

  • 1. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
    Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
    Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.
    Sawczuk IS; Pickens CL; Vasa UR; Ralph DA; Norris KA; Miller MC; Ng AY; Grossman HB; Veltri RW
    Urol Oncol; 2002; 7(5):185-90. PubMed ID: 12644214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human complement factor H related protein test for monitoring bladder cancer.
    Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
    J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP;
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells.
    Bonner RB; Hemstreet GP; Fradet Y; Rao JY; Min KW; Hurst RE
    Cancer; 1993 Oct; 72(8):2461-9. PubMed ID: 8402463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
    Wiener HG; Mian C; Haitel A; Pycha A; Schatzl G; Marberger M
    J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
    Lee KH
    Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
    Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder.
    Mattioli S; Seregni E; Caperna L; Botti C; Savelli G; Bombardieri E
    Int J Biol Markers; 2000; 15(3):219-25. PubMed ID: 11012097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test.
    Raitanen MP; Hellström P; Marttila T; Korhonen H; Talja M; Ervasti J; Tammela TL;
    Eur Urol; 2001 Oct; 40(4):422-6. PubMed ID: 11713397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
    Konety BR; Metro MJ; Melham MF; Salup RR
    Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
    Babjuk M; Kostírová M; Mudra K; Pecher S; Smolová H; Pecen L; Ibrahim Z; Dvorácek J; Jarolím L; Novák J; Zima T
    Eur Urol; 2002 Jan; 41(1):34-9. PubMed ID: 11999463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.